These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8306346)

  • 1. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
    Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
    Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
    Chambers AF; Behrend EI; Wilson SM; Denhardt DT
    Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells.
    Su L; Mukherjee AB; Mukherjee BB
    Oncogene; 1995 Jun; 10(11):2163-9. PubMed ID: 7784060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
    Gardner HA; Berse B; Senger DR
    Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin.
    Chambers AF; Hota C; Prince CW
    Cancer Res; 1993 Feb; 53(3):701-6. PubMed ID: 8425206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
    Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
    Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
    Su ZZ; Austin VN; Zimmer SG; Fisher PB
    Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
    Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
    Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct.
    Perlaky L; Valdez BC; Busch RK; Larson RG; Jhiang SM; Zhang WW; Brattain M; Busch H
    Cancer Res; 1992 Jan; 52(2):428-36. PubMed ID: 1728415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic consequences of down-modulating TIMP expression in 3T3 cells with antisense RNA.
    Denhardt DT; Khokha R; Yagel S; Overall CM; Parhar RS
    Matrix Suppl; 1992; 1():281-5. PubMed ID: 1480038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells.
    Huang W; Carlsen B; Rudkin G; Berry M; Ishida K; Yamaguchi DT; Miller TA
    Bone; 2004 May; 34(5):799-808. PubMed ID: 15121011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.
    Chang PL; Cao M; Hicks P
    Carcinogenesis; 2003 Nov; 24(11):1749-58. PubMed ID: 12919959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cell-substrate adhesion accompanies conditional reversion to the normal phenotype in ras-oncogene-transformed NIH-3T3 cells.
    Shumaker DK; Sklar MD; Prochownik EV; Varani J
    Exp Cell Res; 1994 Oct; 214(2):440-6. PubMed ID: 7925639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ras-responsive genes and tumor metastasis.
    Chambers AF; Tuck AB
    Crit Rev Oncog; 1993; 4(2):95-114. PubMed ID: 8420573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin.
    Furger KA; Allan AL; Wilson SM; Hota C; Vantyghem SA; Postenka CO; Al-Katib W; Chambers AF; Tuck AB
    Mol Cancer Res; 2003 Sep; 1(11):810-9. PubMed ID: 14517343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of calcyclin: tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells.
    Guo XJ; Chambers AF; Parfett CL; Waterhouse P; Murphy LC; Reid RE; Craig AM; Edwards DR; Denhardt DT
    Cell Growth Differ; 1990 Jul; 1(7):333-8. PubMed ID: 2177633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer.
    Sharp JA; Sung V; Slavin J; Thompson EW; Henderson MA
    Lab Invest; 1999 Jul; 79(7):869-77. PubMed ID: 10418827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin expression in mammary gland development and tumorigenesis.
    Rittling SR; Novick KE
    Cell Growth Differ; 1997 Oct; 8(10):1061-9. PubMed ID: 9342184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.